Literature DB >> 1252441

Immunochemical studies of human fibrinopeptide A using synthetic peptide homologues.

G D Wilner, H L Nossel, R E Canfield, V P Butler.   

Abstract

Previous studies have indicated that rabbit antisera R2 and R33 to human fibrinopeptide A differ markedly in terms of cross-reactivity with fibrinogen and fibrinopeptide A-containing fragments of the fibrinogen molecule. Antiserum specificity was characterized by comparison of inhibition of binding to radiolabeled tyrosyl fibrinopeptide A produced by synthetic fragments and enzymatic digests of the fibrinopeptide A molecule vs. the complete fibrinopeptide sequence (Aalpha 1-16). Synthetic COOH-terminal homologues through the dodecapeptide (Aalpha 5-16) exhibited less than 16% immunoreactivity with R33 antiserum, which cross-reacts extensively with fibrinogen and fibrinopeptide A-containing fibrinogen fragments. In contrast, the synthetic COOH-terminal decapeptide (Aalpha 7-16) gave 100% immunoreactivity with R2 antiserum, which cross-reacts minimally with fibrinogen and fibrinopeptide A-containing fibrinogen fragments. Synthetic homologues smaller than Aalpha 7-16, such as Aalpha9-16 and Aalpha 7-11, reacted only minimally with R2 antiserum. Carboxypeptidase B digests of fibrinopeptide A retained less than 25% of their initial immunoreactivity with R2 antiserum. It is concluded that the antigenic determinants of R2 immunoreactivity reside entirely within the COOH-terminal ten-residue sequence of fibrinopeptide A, and that Phe-8, Asp-7, and Arg-16 contribute significantly to R2 immunoreactivity. The R2 antigenic determinants appear to be significantly less accessible to reaction with antibody than the R33 determinants when the fibrinopeptide is attached to its parent alpha chain (Canfield et al., 1976). A possible mechanism for the sequestration is discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1252441     DOI: 10.1021/bi00651a005

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin.

Authors:  J I Weitz; B Leslie
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

2.  Identification of a thrombin sequence with growth factor activity on macrophages.

Authors:  R Bar-Shavit; A J Kahn; K G Mann; G D Wilner
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

3.  Plasma levels of elastase-specific fibrinopeptides correlate with proteinase inhibitor phenotype. Evidence for increased elastase activity in subjects with homozygous and heterozygous deficiency of alpha 1-proteinase inhibitor.

Authors:  J I Weitz; E K Silverman; B Thong; E J Campbell
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

4.  Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.

Authors:  J I Weitz; M K Cruickshank; B Thong; B Leslie; M N Levine; J Ginsberg; T Eckhardt
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

5.  Nature of T lymphocyte recognition of macrophage-associated antigens. V. Contribution of individual peptide residues of human fibrinopeptide B to T lymphocyte responses.

Authors:  D W Thomas; K H Hsieh; J L Schauster; M S Mudd; G D Wilner
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.